When a trip to the doctor for a blood test in 2009 ended with a diagnosis of hepatitis C, Kerrie McKenzie’s first reaction was one of fear. Despite her diagnosis the Tuggeranong resident had to wait until 2016 before she could begin treatment due to most medication being unavailable. “My GP suggested…
Read MoreHepatitis C treatment outcomes using Interferon- and Ribavirin-based therapy in Kigali, Rwanda. By Riedel DJ et al in Trans R Soc Trop Med Hyg. 2016 Sep 12. Abstract BACKGROUND: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at…
Read More
March 8, 2016 According to a recent study, HIV-positive people who contract hepatitis C virus have an increased risk of kidney disease and osteoporosis, even if they spontaneously clear HCV or are cured of the virus. Researchers analyzed data on HIV-positive members of the Swiss HIV Cohort Study, comparing 2,503…
Read More
March 1, 2016 The U.S. Food and Drug Administration (FDA) has approved the single-tablet HIV treatment regimen Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide), which includes a new, safer version of tenofovir. Pronounced “oh-DEF-see,” the tablet is an updated version of Complera (rilpivirine/tenofovir disoproxil fumarate/emtricitabine), swapping tenofovir alafenamide, or TAF, for tenofovir disoproxil fumarate,…
Read More
It is our pleasure to invite you to “The Eighth Annual Conference and Workshop for Gastrointestinal and Liver Diseases for Especialized Centers of Middle Euphrates Governorates and IMI” to be held in Karbal/Iraq from Wednesday, March 16, 2016_ Friday 18, 2016 at the main conference hall, Imam Hussain Medical City.…
Read More